Izvarino Pharma

Corporate functions :

Moscow, Russia

Year of incorporation :

2007

Number of employees :

410

Production Footprint :

Izvarino and Nanopharma (Russia)

Izvarino Pharma provides a professional and competent approach to female healthcare

Established in 2007, Izvarino Pharma is a Russian pharmaceutical company focused on the production, marketing and distribution of high-demand medical products in the Russian market. Today its portfolio includes almost 50 products. The company operates two plants: Izvarino Pharma in Moscow and Nanopharma Development in Kazan. Izvarino also develops innovative technologies for reduced toxicity and improved bio-availability of active pharmaceutical ingredients

Strengths

Izvarino specialises in manufacturing drugs for the treatment of obesity, HIV, cancer, and organ and tissue transplantation and other socially significant diseases. The company’s competitive advantage lies in its expertise in the development of formulations for solid dosage and the latest technological solutions for tablets and capsules.

Izvarino’s focus on obesity is not only pharmaceutical. Driven by the conviction that it can best help patients across their entire lifespan, the company offers an educational program led by endocrinologists. This interactive platform allows patients to safely plan and monitor their tailored response to the challenges they face.

Another of Izvarino’s major strengths lies in the very fact that it is based in Russia. This means that a SEVER company produces essential medication in Russia – especially in the fight against HIV and cancer – and significantly adds to SEVER’s geographical reach. With Izvarino’s two facilities already approved for Good Manufacturing Practice (GMP), this advantage cannot be underestimated: establishing a new company in Russia is fraught with political and bureaucratic difficulties.